ArticleCancer reports (Hoboken, N.J.)2026

Real-World Outcomes With Low-Dose Dasatinib (50 mg) in Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety.

Nandhini Gangadaran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.